Takeda begins US distribution of narcolepsy type 1 drug Orzeyful
Japanese pharma major Takeda has commercially launched Orzeyful (oveporexton) in the US for the treatment for adult patients with narcolepsy type 1.
Japanese pharma major Takeda has commercially launched Orzeyful (oveporexton) in the US for the treatment for adult patients with narcolepsy type 1.
Armada Acquisition has entered a definitive business combination agreement with Brains Bioceutical that values the latter at an implied pre-money equity value of about $750m.
Austria-based GEBRO Holding and Canadian company Spektus Pharma have agreed to a global commercialisation partnership for ActraFlex, an extended-release pain management therapy taken twice a day.
The US Food and Drug Administration (FDA) has approved Asahi Kasei Therapeutics’ Hovilpri (pritelivir) 100mg tablets to treat refractory mucocutaneous herpes simplex virus (HSV) lesions in immunocompromised adults.
Kyowa Kirin’s wholly owned subsidiary Kyowa Kirin International has signed an exclusive distribution agreement with Knight Therapeutics for Poteligeo (mogamulizumab) across selected Latin American markets.
AtomVie Global Radiopharma has opened a purpose-built radiopharmaceutical manufacturing facility in Hamilton, Ontario, Canada, with an investment of more than $160m.
Médunik Canada has entered an exclusive promotional services agreement with Biocodex for Diacomit, a medication approved in Canada as an add-on therapy for seizures associated with Dravet syndrome.
Prestige Consumer Healthcare has agreed to acquire specialty pharmaceuticals provider Akorn Operating Company’s Consumer Health business for approximately $230m.
The US Food and Drug Administration (FDA) has granted priority review for Merck’s New Drug Application (NDA) for the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan.